PolyPid 過去の業績
過去 基準チェック /06
PolyPid has been growing earnings at an average annual rate of 3.1%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.
主要情報
3.1%
収益成長率
83.2%
EPS成長率
Pharmaceuticals 業界の成長 | 6.0% |
収益成長率 | n/a |
株主資本利益率 | -1,542.9% |
ネット・マージン | n/a |
次回の業績アップデート | 13 Nov 2024 |
最近の業績更新
Recent updates
PolyPid set to cut 20% jobs
Oct 20PolyPid's surgical site infections treatment eligible for marketing nod submission in EU
Sep 28PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections
Sep 02PolyPid GAAP EPS of -$1.23 misses by $0.60
Aug 10PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
Aug 03PolyPid: Strong Pipeline, Close Catalysts
Apr 19Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?
Mar 18Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Nov 08We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth
Jul 15Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Mar 09PolyPid's oncoplex cancer program shows encouraging action in animal study
Dec 22PolyPid launches second late-stage trial with D-PLEX100 in surgical infections
Dec 16PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections
Nov 24収支内訳
PolyPid の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 0 | -25 | 5 | 18 |
31 Mar 24 | 0 | -24 | 6 | 17 |
31 Dec 23 | 0 | -24 | 7 | 16 |
30 Sep 23 | 0 | -24 | 7 | 16 |
30 Jun 23 | 0 | -28 | 8 | 19 |
31 Mar 23 | 0 | -34 | 10 | 23 |
31 Dec 22 | 0 | -40 | 11 | 28 |
30 Sep 22 | 0 | -46 | 13 | 33 |
30 Jun 22 | 0 | -47 | 13 | 34 |
31 Mar 22 | 0 | -46 | 13 | 33 |
31 Dec 21 | 0 | -43 | 13 | 31 |
30 Sep 21 | 0 | -41 | 11 | 26 |
30 Jun 21 | 0 | -37 | 11 | 23 |
31 Mar 21 | 0 | -46 | 11 | 20 |
31 Dec 20 | 0 | -43 | 9 | 17 |
30 Sep 20 | 0 | -42 | 8 | 15 |
30 Jun 20 | 0 | -37 | 6 | 15 |
31 Mar 20 | 0 | -19 | 5 | 14 |
31 Dec 19 | 0 | -13 | 4 | 14 |
31 Dec 18 | 0 | 0 | 6 | 13 |
31 Dec 17 | 0 | -59 | 4 | 10 |
30 Sep 17 | 0 | -20 | 3 | 9 |
31 Dec 16 | 0 | -14 | 3 | 8 |
31 Dec 15 | 0 | -11 | 3 | 6 |
30 Jun 14 | 0 | -6 | 1 | 2 |
31 Mar 14 | 0 | -5 | 1 | 3 |
質の高い収益: PYPD is currently unprofitable.
利益率の向上: PYPD is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: PYPD is unprofitable, but has reduced losses over the past 5 years at a rate of 3.1% per year.
成長の加速: Unable to compare PYPD's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: PYPD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
株主資本利益率
高いROE: PYPD has a negative Return on Equity (-1542.91%), as it is currently unprofitable.